Share

Helmholtz Zentrum München Allies with Eli Lilly and Company to Discover New Targets for Pancreatic Beta Cell Regeneration in the Treatment of Diabetes

The Institute of Diabetes and Regeneration Research at Helmholtz Zentrum München and Eli Lilly and Company (Lilly) have partnered with the goal of improving and accelerating the treatment of diabetes mellitus. Diabetes mellitus’s long-term complications and co-morbidities represent one of the most devastating and urgent threats to society. While significant progress has been made in...
Share

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating...
Share

In Living Color: Extending Your Practice’s Reach Via Telehealth

The advent of smart phones has enabled patients to avoid lengthy travel and made languishing in waiting rooms a thing of the past as telehealth has become more and more common in endocrinology practices. Telehealth can help manage the kind of chronic conditions, such as hypothyroidism or diabetes, that are considered hallmarks of endocrinology. Such...
Share

FDA Approves First Ready-to-Use Stable Liquid Glucagon for Severe Hypoglycemia

The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
Share

FDA Approves First Treatment for Severe Hypoglycemia That Can Be Administered without an Injection

BAQSIMI Product Photo - Final In July, the U.S. Food and Drug Administration approved a nasal powder glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection. Eli Lilly and Company is marketing the drug as Baqsimi. The therapy has been approved to treat severe hypoglycemia in patients with diabetes ages four and older....

The endocrine system is a miracle of evolution — a highly complex machine that carries out multiple functions within the body with precision and efficiency. It’s no wonder that as our understanding of the endocrine system advances, the technology we use to study and care for it also becomes more advanced as it approaches the endocrine system in terms of sophistication. Whether that endocrinology technology takes the form of new, advanced medicines, sophisticated imaging and diagnostic technology, or innovative therapies that make life easier for patients, endocrine science continues to push the boundaries and enter new territory. For endocrinologists, staying informed about all of the latest advances in technology and effective treatment options mean better overall care for their patients.

This section compiles the latest news regarding technological advances in endocrinology, featuring articles written for and by the leading voices in endocrine science today. Here, you’ll find articles relating to all the most recent happenings in technology, techniques and general information of interest to endocrinologists. Keeping up with the latest advancements in the field will help you know where medicine has been, where it will advance next, and how it will look in the future. Endocrine News brings you everything you need to know about the future of endocrinology so you’ll know exactly when science catches up to your patients’ needs. The field of endocrinology continues to advance, and Endocrine News is your source for advancing your own knowledge of everything that’s going on for today and tomorrow.